IS4023A - Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT) - Google Patents

Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT)

Info

Publication number
IS4023A
IS4023A IS4023A IS4023A IS4023A IS 4023 A IS4023 A IS 4023A IS 4023 A IS4023 A IS 4023A IS 4023 A IS4023 A IS 4023A IS 4023 A IS4023 A IS 4023A
Authority
IS
Iceland
Prior art keywords
acat
aryl
new
production
act against
Prior art date
Application number
IS4023A
Other languages
English (en)
Inventor
S. Hamanaka Ernest
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4023A publication Critical patent/IS4023A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
IS4023A 1992-05-28 1993-05-24 Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT) IS4023A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89005092A 1992-05-28 1992-05-28

Publications (1)

Publication Number Publication Date
IS4023A true IS4023A (is) 1993-11-29

Family

ID=25396173

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4023A IS4023A (is) 1992-05-28 1993-05-24 Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT)

Country Status (23)

Country Link
US (1) US6001860A (is)
EP (1) EP0642498A1 (is)
JP (1) JPH07503737A (is)
KR (1) KR950701621A (is)
CN (1) CN1080919A (is)
AU (1) AU4028393A (is)
BG (1) BG99188A (is)
BR (1) BR9306421A (is)
CA (1) CA2134359C (is)
FI (1) FI932423A7 (is)
HR (1) HRP930931A2 (is)
HU (1) HUT64303A (is)
IL (1) IL105756A0 (is)
IS (1) IS4023A (is)
MA (1) MA22896A1 (is)
MX (1) MX9303100A (is)
OA (1) OA10114A (is)
PL (1) PL299082A1 (is)
RU (1) RU94046149A (is)
SK (1) SK142694A3 (is)
UY (1) UY23589A1 (is)
WO (1) WO1993024458A1 (is)
YU (1) YU37193A (is)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
NZ250916A (en) * 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
IL109568A0 (en) * 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ES2076865B1 (es) * 1993-07-05 1996-08-01 Pfizer Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat).
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
US6133326A (en) * 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
EP0784612A1 (en) * 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
HUP9602538A3 (en) 1995-09-18 1997-08-28 Sankyo Co New urea and amide derivatives having acat inhibitory activity, their preparation and their use
BR9711342A (pt) 1996-08-22 1999-08-17 Warner Lambert Co Antagonistas de receptor de bombesina nÆo-pept¡do
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP1028953A1 (en) * 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
EP1157026A1 (en) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
PL350357A1 (en) 1999-03-12 2002-12-02 Boehringer Ingelheim Pharma Heterocyclic urea and related compounds useful as anti−inflammatory agents
DE60023853T2 (de) 1999-03-12 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
EP1200411B1 (en) 1999-07-09 2005-12-14 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds
JP4955171B2 (ja) 1999-11-16 2012-06-20 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての尿素誘導体
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
EE200200429A (et) 2000-02-02 2003-12-15 Warner-Lambert Company Kolesteroolestri ja vahaestri sünteesi duaalsed inhibiitorid rasunäärme häirete jaoks
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2445003A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
RU2374236C2 (ru) * 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
JP4629978B2 (ja) 2002-02-25 2011-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US7399866B2 (en) * 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
MXPA06014495A (es) 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
CA2614518A1 (en) * 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
ES2382815T3 (es) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) * 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959962A2 (en) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
JP5015496B2 (ja) 2006-06-01 2012-08-29 ルネサスエレクトロニクス株式会社 固体撮像装置、撮像方法および撮像システム
CN101541758A (zh) * 2006-08-25 2009-09-23 艾博特公司 抑制trpv1的吲唑衍生物及其用途
WO2008079683A2 (en) 2006-12-20 2008-07-03 Abbott Laboratories N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
US8138185B2 (en) * 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
US8318778B2 (en) 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
KR20100090689A (ko) * 2007-10-19 2010-08-16 애보트 게엠베하 운트 콤파니 카게 Ｎ―아릴 우레아계 화합물을 함유하는 고체 분산액 생성물
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
CN102036969A (zh) * 2008-03-20 2011-04-27 雅培制药有限公司 制造作为trpv1拮抗剂的中枢神经系统药剂的方法
CN103172543B (zh) * 2011-12-21 2016-02-10 中国科学院上海药物研究所 一种脲类化合物、制备方法及其用途
TWI539385B (zh) 2015-01-28 2016-06-21 金佶科技股份有限公司 光動能指紋辨識模組
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
JP7728367B2 (ja) 2021-06-14 2025-08-22 スコーピオン・セラピューティクス・インコーポレイテッド がんを処置するために使用され得る尿素誘導体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426031A (en) * 1967-01-19 1969-02-04 Dow Chemical Co 3,5,6 - trichloro - 4 - (3 - (alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro - 3,5 - xylyl)ureido) picolinic acid and the corresponding amide derivative
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US4751026A (en) * 1986-03-24 1988-06-14 Warner-Lambert Company Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en) * 1986-04-28 1988-02-02 Warner-Lambert Company Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
EP0252524A3 (en) * 1986-07-11 1989-04-19 Warner-Lambert Company Aryl- and aralkylamide- derivatives of omega- (substituted-phenyloxy)-alkanoic acids as inhibitors of acyl-coa: cholesterol acyltransferase and pharmaceuticals containing them
US4716175A (en) * 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
US4743605A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase
US5015644A (en) * 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
IE61716B1 (en) * 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
EP0297610B1 (en) * 1987-07-02 1991-03-13 Warner-Lambert Company N-[(2,6-disubstituted)phenyl]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase
US5116848A (en) * 1988-03-30 1992-05-26 Warner-Lambert Company N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5155127A (en) * 1989-02-09 1992-10-13 Warner-Lambert Company N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
CA2010184A1 (en) * 1989-02-17 1990-08-17 Bharat K. Trivedi Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
US4994465A (en) * 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
CA2022346A1 (en) * 1989-08-04 1991-02-05 Mitsubishi Chemical Corporation 1-phenylalkyl-3-phenylurea derivatives
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
TW205037B (is) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH05310678A (ja) * 1990-01-22 1993-11-22 Mitsubishi Kasei Corp １−フェニルアルキル−３−フェニル尿素誘導体
AU7440691A (en) * 1990-03-12 1991-10-10 Yamanouchi Pharmaceutical Co., Ltd. Monourea derivative and its salt
EP0447116B1 (en) * 1990-03-12 1994-12-14 Yamanouchi Pharmaceutical Co. Ltd. Urea derivatives, their production, and pharmaceutical compositions containing them
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
IL101785A0 (en) * 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)

Also Published As

Publication number Publication date
HUT64303A (en) 1993-12-28
EP0642498A1 (en) 1995-03-15
HU9301552D0 (en) 1993-09-28
CN1080919A (zh) 1994-01-19
FI932423L (fi) 1993-11-29
CA2134359A1 (en) 1993-12-09
FI932423A0 (fi) 1993-05-27
PL299082A1 (en) 1994-04-05
IL105756A0 (en) 1993-09-22
RU94046149A (ru) 1996-11-27
BG99188A (bg) 1995-07-28
US6001860A (en) 1999-12-14
OA10114A (en) 1996-12-18
MA22896A1 (fr) 1993-12-31
CA2134359C (en) 1997-07-01
MX9303100A (es) 1994-06-30
BR9306421A (pt) 1998-09-15
SK142694A3 (en) 1995-06-07
AU4028393A (en) 1993-12-30
UY23589A1 (es) 1993-11-15
HRP930931A2 (en) 1997-06-30
WO1993024458A1 (en) 1993-12-09
JPH07503737A (ja) 1995-04-20
YU37193A (sh) 1997-07-31
KR950701621A (ko) 1995-04-28
FI932423A7 (fi) 1993-11-29

Similar Documents

Publication Publication Date Title
IS4023A (is) Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT)
IS4148A (is) Hliðstæð aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum
ZA9710038B (en) Method for the production of levulinic acid and its derivatives
AU617818B2 (en) A corrugated pipe, a method of forming the corrugated pipe and an apparatus for manufacturing the same
IS3994A (is) Hliðstæð aðferð til framleiðslu á indole afleiðum
GB2293629B (en) A turbomachine aerofoil and a method of production
FI943841L (fi) Liitin laipoitetuille putkille, prosessi laippojen liittämiseksi ja liittimen käyttö
IS3919A (is) Hliðstæð aðferð til framleiðslu á heteróarýl amínum sem mynda nýja asetýlkólínesterasatálma
HUP9702042A3 (en) Use of 1,1,2-triphenil but-1-ene derivatives for the production of medicaments against atherosclerosis
EP0913496A4 (en) PART COATED BY HIGH-TEMPERATURE SPRAYING AND METHOD FOR THE PRODUCTION THEREOF
PT770687E (pt) Processo para a producao de nicotinamida
DE69514438D1 (de) Mikrowellenoszillator und Verfahren zu dessen Herstellung
GB9027535D0 (en) A corrosion-inhibiting coating,and method of forming same
PL306730A1 (en) Derivatives of alpha-pyrimidinylacrylic acid, method of obtaining them and their applications
ZA94441B (en) An application and method for the production of N-cyclic and N,N'-dicyclic ureas
HU9501041D0 (en) Peptide-boronic acid derivatives, process for producing them and pharmaceutical application thereof
PL312693A1 (en) Oxathiolanes, method of their production and pharmaceutical compounds containing them
NO304949B1 (no) Nye glukose- og soforoselipider, en fremgangsmÕte for fremstilling derav og anvendelse av lipidene
HU911984D0 (en) Process for the production of dialkyl piridine-2,3-diacarboxylate and its derivatives
PL320536A1 (en) Derivatives of 3-benzoylopyridine, their production and application as herbicides
DK46894A (da) Ranitidintablet med et hydroxypropylmethylcelluloseholdigt overtræk samt fremgangsmåde til at tilvejebringe dette overtræk
IS4033A (is) Hliðstæð aðferð til framleiðslu á isobenzofuranylafleiðum og milliefni til notkunar með aðferðinni
GB2303862B (en) A ceiling and a method of constructing the same
ZA96518B (en) Method and apparatus for tacking intended for the assembly of a crane girder casing
HUP9900170A3 (en) Zwitterionic forms of trovafloxacin, process for producing them and medicaments containing the same